PL377426A1 - Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego - Google Patents

Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego

Info

Publication number
PL377426A1
PL377426A1 PL377426A PL37742603A PL377426A1 PL 377426 A1 PL377426 A1 PL 377426A1 PL 377426 A PL377426 A PL 377426A PL 37742603 A PL37742603 A PL 37742603A PL 377426 A1 PL377426 A1 PL 377426A1
Authority
PL
Poland
Prior art keywords
sup
antagonists
receptor agonists
serotonin receptor
novel compounds
Prior art date
Application number
PL377426A
Other languages
English (en)
Inventor
Taekyu Lee
Wenting Chen
Wei Deng
Albert Robichaud
Ruth Wexler
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL377426A1 publication Critical patent/PL377426A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL377426A 2002-12-19 2003-12-19 Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego PL377426A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43476002P 2002-12-19 2002-12-19

Publications (1)

Publication Number Publication Date
PL377426A1 true PL377426A1 (pl) 2006-02-06

Family

ID=32682101

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377426A PL377426A1 (pl) 2002-12-19 2003-12-19 Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego

Country Status (10)

Country Link
US (1) US7109339B2 (pl)
EP (1) EP1581221B1 (pl)
JP (1) JP4486505B2 (pl)
AT (1) ATE509929T1 (pl)
AU (1) AU2003303210A1 (pl)
ES (1) ES2364046T3 (pl)
IS (1) IS7891A (pl)
NO (1) NO20052728L (pl)
PL (1) PL377426A1 (pl)
WO (1) WO2004056324A2 (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007275A (es) * 2001-02-16 2003-12-04 Bristol Myers Squibb Co Identificacion y clonacion de gen humano novedoso, ret16 involucrado en cascada de senalizacion intracelular.
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
CA2564018A1 (en) * 2004-03-05 2005-10-13 Pharma C S.A. 8-phenoxy-.gamma. carboline derivatives
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
US7572805B2 (en) * 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
AU2005305036B2 (en) * 2004-11-01 2011-03-10 Amylin Pharmaceuticals, Llc Treatment of obesity and related disorders
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
AR052227A1 (es) * 2004-11-05 2007-03-07 Wyeth Corp Metabolitos derivados de [1,4] diazepin [ 6,7,1-ij] quinolina, metodos de preparacion y usos de los mismos
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
AU2006275694A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
CN101243050B (zh) 2005-08-31 2012-07-04 霍夫曼-拉罗奇有限公司 吡唑啉酮衍生物
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
RU2329044C1 (ru) * 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
CN101796051B (zh) * 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
RU2338745C1 (ru) * 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
AU2008257152A1 (en) * 2007-05-25 2008-12-04 Medivation Neurology, Inc. Methods and compositions for stimulating cells
AU2008269513B2 (en) 2007-06-26 2011-06-16 Astrazeneca Ab 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors
MX2010003149A (es) * 2007-09-20 2010-11-10 D2E Llc Derivados que contienen fluor de pirido[4,3-b]indoles hidrogenados con propiedades neuroprotectoras y de mejoramiento de cognicion, proceso de preparacion y uso.
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
EP2560676B8 (en) * 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CA2823955A1 (en) 2011-01-19 2012-07-26 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
EP2836211B1 (en) 2012-04-14 2019-03-20 Intra-Cellular Therapies, Inc. Treatment of PTSD and impulse control disorders
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
IL321987A (en) 2013-12-03 2025-09-01 Intra Cellular Therapies Inc A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders
CN106456638A (zh) 2014-04-04 2017-02-22 细胞内治疗公司 有机化合物
WO2015154025A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
CA3011983A1 (en) 2016-01-26 2017-08-03 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines
EP3407889B1 (en) 2016-03-25 2021-05-19 Intra-Cellular Therapies, Inc. Organic compounds and their use in treating or preventing central nervous system disorders
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP6997718B2 (ja) 2016-03-28 2022-01-18 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規共結晶
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規塩類および結晶
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018111805A1 (en) * 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018175969A1 (en) 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2018200959A1 (en) * 2017-04-28 2018-11-01 France Charles Methods and composition related to combination therapy for addiction
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment
KR102899502B1 (ko) 2017-07-26 2025-12-11 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
MX2020007271A (es) 2017-09-26 2020-08-17 Intra Cellular Therapies Inc Sales y cristales novedosos.
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
MX2020009928A (es) 2018-03-23 2021-01-08 Intra Cellular Therapies Inc Compuestos organicos.
EP3628007B1 (en) 2018-06-06 2023-05-03 Intra-Cellular Therapies, Inc. Novel salts and crystals
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
EP3609891B1 (en) 2018-06-11 2026-02-11 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
KR20210052472A (ko) 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
EP3952864A4 (en) * 2019-03-08 2023-05-10 The Regents of the University of California COMPOSITIONS AND METHODS FOR MODULATION OF LIPID AND STEROID METABOLISM
BR112022000231A2 (pt) 2019-07-07 2022-02-22 Intra Cellular Therapies Inc Novos métodos
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2023288027A1 (en) * 2021-07-14 2023-01-19 Northeastern University Serotonin 5-ht2a, 5-ht2b, and 5-ht2c receptor inverse agonists
CN114105985B (zh) * 2021-12-13 2024-04-16 南方科技大学坪山生物医药研究院 不对称氢化构建卢美哌隆中间体的方法及卢美哌隆中间体
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
HUT61548A (en) 1990-08-27 1993-01-28 Sandoz Ag Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds
JP3108483B2 (ja) * 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
TW470745B (en) * 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
SK8192001A3 (en) 1998-12-17 2001-12-03 American Home Prod 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivatives being 5ht2c agonists
MXPA01012914A (es) 1999-06-15 2004-04-21 Bristol Myers Squibb Co Gama-carbolinas fundidas de heterociclo substituido.
MXPA03005438A (es) 2000-12-20 2004-05-05 Bristol Myers Squibb Co Pirioindoles substituidos como agonistas y antagonistas de serotonina.
JP2005526691A (ja) * 2001-08-08 2005-09-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療剤1H−ピリド[4,3−b]インドール

Also Published As

Publication number Publication date
AU2003303210A1 (en) 2004-07-14
NO20052728L (no) 2005-08-23
EP1581221A2 (en) 2005-10-05
WO2004056324A2 (en) 2004-07-08
WO2004056324A3 (en) 2004-09-02
US7109339B2 (en) 2006-09-19
JP4486505B2 (ja) 2010-06-23
ES2364046T3 (es) 2011-08-23
JP2006511568A (ja) 2006-04-06
IS7891A (is) 2005-06-10
ATE509929T1 (de) 2011-06-15
EP1581221B1 (en) 2011-05-18
US20040180875A1 (en) 2004-09-16
EP1581221A4 (en) 2008-11-26
NO20052728D0 (no) 2005-06-07
AU2003303210A8 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
AU2003303210A8 (en) Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
IL156261A0 (en) Pyrroloquinoline and pyridoquinoline derivatives and pharmaceutical compositions containing the same
WO2002059129A3 (en) Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
HK1043112A1 (zh) 取代的稠杂环γ-咔啉
NO20080317L (no) Substituerte tetrahydro-1H-Pyrido[4,3-B]Indoler som serotonin reseptor-agonister og antagonister
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
EP1392298A4 (en) FOUNDED HETEROCYCLIC COMPOUNDS
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
WO2004089312A3 (en) New piperidinylamino-thieno[2,3-d] pyrimidine compounds
PL366060A1 (pl) Podstawione pochodne pirazynochinoksaliny jako agoniści i antagoniści receptora serotoninowego
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses
WO2004018482A8 (en) C6- and c9-substituted chromeno[4, 3-c]isoxazoline derivatives and their use as anti-depressants
WO2004080407A3 (en) New serotonin modulating compounds and uses therefor

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)